Cargando…

Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders

PURPOSE OF REVIEW: Despite clear evidence that sex differences largely impact the efficacy and tolerability of antipsychotic medication, current treatment guidelines for schizophrenia spectrum disorders (SSD) do not differentiate between men and women. This review summarizes the available evidence o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brand, Bodyl A., Willemse, Elske J. M., Hamers, Iris M. H., Sommer, Iris E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654163/ https://www.ncbi.nlm.nih.gov/pubmed/37864676 http://dx.doi.org/10.1007/s11920-023-01460-6

Ejemplares similares

Antipsychotic medication for women with schizophrenia spectrum disorders
por: Brand, Bodyl A., et al.
Publicado: (2022)

Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse
por: Sommer, Iris E, et al.
Publicado: (2022)

Antipsychotic medication for women with schizophrenia spectrum disorders – CORRIGENDUM
por: Brand, Bodyl A., et al.
Publicado: (2023)

The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical Trial
por: Brand, Bodyl A, et al.
Publicado: (2023)

S57. CHARACTERIZING COGNITIVE HETEROGENEITY IN INDIVIDUALS WITH A SCHIZOPHRENIA SPECTRUM DISORDER: A CLUSTER ANALYTIC APPROACH
por: Brand, Bodyl
Publicado: (2020)

Estrogens in schizophrenia: progress, current challenges and opportunities
por: Brand, Bodyl A., et al.
Publicado: (2021)

Raloxifene augmentation in men and women with a schizophrenia spectrum disorder: A study protocol
por: Brand, Bodyl A., et al.
Publicado: (2020)

Efficacy of non-invasive brain stimulation on cognitive functioning in brain disorders: a meta-analysis
por: Begemann, Marieke J., et al.
Publicado: (2020)

T73. COGNITIVE CLUSTERING IN SCHIZOPHRENIA SPECTRUM DISORDER AND THE ASSOCIATION WITH BRAIN VOLUME
por: Oomen, Priscilla, et al.
Publicado: (2020)

The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis
por: de Boer, Janna, et al.
Publicado: (2018)

Functional brain networks in the schizophrenia spectrum and bipolar disorder with psychosis
por: van Dellen, Edwin, et al.
Publicado: (2020)

Association between gut permeability, brain volume, and cognition in healthy participants and patients with schizophrenia spectrum disorder
por: Scheurink, Toon Anton Willem, et al.
Publicado: (2023)

O7.6. META-ANALYSIS OF EFFICACY OF COGNITIVE ENHANCERS FOR PATIENTS WITH SCHIZOPHRENIA-SPECTRUM DISORDERS
por: Sinkeviciute, Igne, et al.
Publicado: (2018)

Pharmacologic treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2010)

Updated evidence-based recommendations for cervical cancer screening in France
por: Hamers, Françoise F., et al.
Publicado: (2021)

The clinical course of schizophrenia in women and men—a nation-wide cohort study
por: Sommer, Iris E., et al.
Publicado: (2020)

Schizophrenia: family studies and treatment of spectrum disorders
por: Tsuang, Ming T., et al.
Publicado: (2000)

Consensus Panel Recommendations for the Pharmacological Management of Pregnant Women with Depressive Disorders
por: Eleftheriou, Georgios, et al.
Publicado: (2023)

Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study
por: Hoekstra, Sanne, et al.
Publicado: (2021)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Drug‐naïve first‐episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China
por: Zhu, Mengran, et al.
Publicado: (2020)

Optical coherence tomography reveals retinal thinning in schizophrenia spectrum disorders
por: Boudriot, Emanuel, et al.
Publicado: (2022)

Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

T59. ACOUSTIC SPEECH MARKERS FOR SCHIZOPHRENIA
por: de Boer, Janna, et al.
Publicado: (2020)

Evidence of a Causal Relationship Between Smoking Tobacco and Schizophrenia Spectrum Disorders
por: Scott, James G., et al.
Publicado: (2018)

Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders
por: Manchia, Mirko, et al.
Publicado: (2022)

Inflammatory monocyte gene signature predicts beneficial within group effect of simvastatin in patients with schizophrenia spectrum disorders in a secondary analysis of a randomized controlled trial
por: Aichholzer, Mareike, et al.
Publicado: (2022)

Language and turn-taking in schizophrenia spectrum disorders
por: Dusi, L., et al.
Publicado: (2022)

The Pharmacological Shock Treatment of Schizophrenia
Publicado: (1938)

Turning the Spotlight on Apathy: Identification and Treatment in Schizophrenia Spectrum Disorders
por: Lyngstad, Siv Hege, et al.
Publicado: (2023)

Understanding the Impact of Menopause on Women With Schizophrenia-Spectrum Disorders: A Comprehensive Review
por: Tiwari, Swasti, et al.
Publicado: (2023)

Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial
por: Sommer, Iris E, et al.
Publicado: (2021)

Risk and Protective Environmental Factors Associated with Autism Spectrum Disorder: Evidence-Based Principles and Recommendations
por: Emberti Gialloreti, Leonardo, et al.
Publicado: (2019)

Neuroretinal Biomarkers for Schizophrenia Spectrum Disorders
por: Asanad, Samuel, et al.
Publicado: (2021)

Subcortical neuromorphometry in schizophrenia spectrum and bipolar disorders
por: Mamah, Daniel, et al.
Publicado: (2016)

Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode
por: Keating, Dolores, et al.
Publicado: (2017)

Characterizing the sensorimotor domain in schizophrenia spectrum disorders
por: Fritze, Stefan, et al.
Publicado: (2021)

Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What’s the Evidence?
por: Vingerhoets, Wilhelmina A. M., et al.
Publicado: (2013)

S209. DRUG-NAïVE FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDERS: PHARMACOLOGICAL TREATMENT PRACTICES IN INPATIENT UNITS IN HUNAN PROVINCE, CHINA
por: Zhu, Mengran, et al.
Publicado: (2020)

Evidence and consensus recommendations for the pharmacological management of pain in India
por: Dureja, Gur Prasad, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g7bb1t9rcc2iudrnc460p12c67